Kenvue (NYSE:KVUE) Price Target Lowered to $18.00 at UBS Group

Kenvue (NYSE:KVUE) had its price target trimmed by UBS Group from $19.00 to $18.00 in a research note released on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms have also recently issued reports on KVUE. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday, March 6th. Citigroup upped their target price on shares of Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th. Finally, Canaccord Genuity Group upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.50.

Kenvue Stock Performance

Shares of Kenvue stock opened at $16.73 on Tuesday. The stock has a market cap of $32.06 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 3.89 and a beta of 0.61. The firm’s 50-day moving average is $17.96 and its 200 day moving average is $17.06. Kenvue has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. Kenvue’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.26 EPS. Sell-side analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 5.0%. Kenvue’s dividend payout ratio is presently 107.79%.

Institutional Investors Weigh In On Kenvue

Hedge funds and other institutional investors have recently made changes to their positions in the business. Salomon & Ludwin LLC purchased a new stake in shares of Kenvue during the 3rd quarter valued at about $25,000. NBT Bank N A NY increased its position in shares of Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the last quarter. Cornerstone Planning Group LLC increased its position in shares of Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after purchasing an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. increased its position in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Kenvue during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.